A Comparison of Salmeterol with Albuterol in the Treatment of Mild-to-Moderate Asthma
Open Access
- 12 November 1992
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 327 (20) , 1420-1425
- https://doi.org/10.1056/nejm199211123272004
Abstract
An effective, long-acting bronchodilator could benefit patients with asthma who have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting, inhaled β2-adrenoceptor agonist, salmeterol, with a short-acting β2-agonist, albuterol, in the treatment of mild-to-moderate asthma.Keywords
This publication has 12 references indexed in Scilit:
- Salmeterol, a new inhaled beta2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstrictionJournal of Allergy and Clinical Immunology, 1992
- Salmeterol, a novel, long‐acting β2‐adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivoBritish Journal of Pharmacology, 1991
- Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.BMJ, 1990
- Protection against allergen-induced asthma by salmeterolThe Lancet, 1990
- Regular inhaled beta-agonist treatment in bronchial asthmaThe Lancet, 1990
- Inhaled Salmeterol and Salbutamol in Asthmatic Patients: An Evaluation of Asthma Symptoms and the Possible Development of TachyphylaxisAmerican Review of Respiratory Disease, 1990
- A New Approach to the Treatment of AsthmaNew England Journal of Medicine, 1989
- Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.Thorax, 1988
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987
- Regular versus symptomatic aerosol bronchodilator treatment of asthmaRespiratory Medicine, 1981